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Abstract Lipoprotein lipase (LPL) is a hydrolase that
cleaves circulating triglycerides to release fatty acids to
the surrounding tissues. The enzyme is synthesized in
parenchymal cells and is transported to its site of action on
the capillary endothelium by glycophosphatidylinositol
(GPI)-anchored high-density lipoprotein-binding protein 1
(GPIHBP1). Inactivating mutations in LPL; in its cofactor,
apolipoprotein (Apo) C2; or in GPIHBP1 cause severe
hypertriglyceridemia. Here we describe an individual with
complete deficiency of GPIHBP1. The proband was an
Asian Indian boy who had severe chylomicronemia at 2
months of age. Array-based copy-number analysis of his
genomic DNA revealed homozygosity for a 17.5-kb
deletion that included GPIHBP1. A 44-year-old aunt with
a history of hypertriglyceridemia and pancreatitis was also
homozygous for the deletion. A bolus of intravenously
administered heparin caused a rapid increase in circulating
LPL and decreased plasma triglyceride levels in control
individuals but not in two GPIHBP1-deficient patients.
Thus, short-term treatment with heparin failed to attenuate the
hypertriglyceridemia in patients with GPIHBP1 deficiency.
The increasing resolution of copy number microarrays and
their widespread adoption for routine cytogenetic analysis is
likely to reveal a greater role for submicroscopic deletions in
Mendelian conditions. We describe the first neonate with
complete GPIHBP1 deficiency due to homozygosity for a
deletion of GPIHBP1.
Introduction
Type I hyperlipoproteinemia is a rare, autosomal recessive
disorder characterized by the accumulation of large
triglyceride-rich lipoproteins in the circulation (chylomi-
cronemia), which leads to the development of eruptive
xanthomas, failure to thrive, and recurrent pancreatitis
(Brunzell and Deeb 2001). The disorder is caused by
mutations that disrupt the lipolytic processing of triglyceride-
rich lipoproteins, including inactivating mutations in genes
encoding lipoprotein lipase (LPL) (Havel and Gordon 1960),
the enzyme that hydrolyzes circulating triglycerides; its
cofactor, APOC2 (Breckenridge et al. 1978); a lipase-
specific chaperone known as lipase maturation factor 1
(Peterfy et al. 2007); and the protein that anchors the enzyme
to the endothelial surface, glycophosphatidylinositol
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1 (GPIHBP1) (Beigneux et al. 2007). GPIHBP1 was
originally identified as a high-density lipoprotein (HDL)-
binding protein (Ioka et al. 2003), but the subsequent
finding that Gpihbp1 knockout mice have severe hyper-
triglyceridemia revealed an essential role for the protein in
the action of LPL at capillary endothelial surfaces (Beigneux
et al. 2007). LPL is synthesized primarily by adipocytes,
skeletal myocytes, and cardiomyocytes and is secreted into
the extracellular space where it binds proteoglycans (Brunzell
and Deeb 2001). GPIHBP1 binds LPL in the capillary
subendothelial spaces and translocates the enzyme to the
luminal surfaces of endothelial cells (Davies et al. 2010). In
mice lacking GPIHBP1, heparin-releasable LPL activity is
reduced (Beigneux et al. 2007). GPIHBP1 appears to
function as a platform for lipolysis of circulating triglycerides
(Beigneux et al. 2007).
Human GPIHBP1 is located on the distal long arm of
chromosome 8 and encodes a 184-amino-acid protein that
contains three domains: N-terminal highly acidic, lympho-
cyte antigen (Ly6), and C-terminal to which the glyco-
phosphatidylinositol is attached (Beigneux et al. 2009a).
Mutations in the acidic and Ly6 domains interfere with the
ability of GPIHBP1 to bind LPL and chylomicrons
(Beigneux et al. 2009c; Gin et al. 2008). Several mutations
in GPIHBP1 gene have been identified in patients with
chylomicronemia (Table 1). Here, we describe the first
reported patient with a complete absence of GPIHBP1 due
to a deletion of GPIHBP1 and assess the therapeutic
efficacy of heparin in this individual and in a second
patient with hypertriglyceridemia who was homozygous for
missense mutation c.203 G >A (p.Cys68Tyr) in GPIHBP1.
Materials and methods
Study participants The study was approved by the Institu-
tional Review Board of the University of Texas Southwestern
MedicalCenter,USA.Writteninformedconsentwasobtained
from all participants prior to collecting venous blood after a
12-h fast. Genomic DNA was extracted using the Gentra
PuregeneBlood Kit(Qiagen,Valencia,CA,USA)ortheEasy-
DNA kit (Invitrogen, Carlsbad, CA,USA) following the
manufacturers’ protocol. Fasting plasma lipids and lipopro-
teins were measured by Quest Diagnostics.
Sequencing coding regions of candidate genes The exons
of LPL, APOC2, APOA5, and LMF1 were amplified from
50 ng of genomic DNA using the polymerase chain
reaction (PCR) and oppositely oriented oligonucleotides
that flank the exons of these genes (Supplementary Table 1).
Amplification products were sequenced using dye-
terminator chemistry and an ABI 3730xl DNA analyzer.
Sequence variants were verified by manually inspecting
chromatograms.
Genotyping and copy number variation (CNV) detection Array-
based single nucleotide polymorphism (SNP) genotyping
was performed on genomic DNA from proband 1 using the
human 1-M Beadchip (Illumina, San Diego, CA, USA)
according to the manufacturer’s Infinium II Assay protocol.
Briefly, 750 ng of genomic DNA was amplified, enzymat-
ically fragmented, and precipitated with isopropanol, as
described (Illumina’s Infinium II Assay). The fragmented
genomic DNA was hybridized with an Illumina Human 1-M
beadchip that contained 50-mer probes attached to a silicon-
based array that interrogates 1,072,820 SNP. A single-base
extension reaction was performed to label the annealed DNA
in an allele-specific manner. The hybridized array was
scanned using the Illumina BeadArray Reader to image the
laser-excited fluorophores for each probe. Data was analyzed
using the BeadstudioGenotypingModule(v3.3.7). Individual
probe log ratios [logR = log2 (sample intensity/expected
reference intensity)] were plotted by their genomic positions
using the Genome Browser in the Illumina Genome Viewer
(v3.2.9). A smoothing line was generated using a 200-kb
moving average window to enhance visualization of the
copy number gains and losses in the Genome Viewer.
Probe-intensity data was analyzed using Partek Genomic
Suite software (Partek, St. Louis, MO, USA). Briefly, copy
number was estimated from intensity values relative to
baseline copy number calculated from array results of seven
unrelated individuals with other genetic disorders. Genomic
segmentation algorithms were used to identify genomic
regions that differed significantly in signal intensity.
Genotype data was imported into Partek Genomic Suite
software and analyzed using a Hidden Markov Model
(Churchill 1989) to identify regions of homozygosity. For
comparison, we examined genotype data from an offspring of
a second-cousin mating and from six European Americans
who were offspring of nonconsanguinious matings. Size
distributions of the regions of homozygosity are represented
a saq u a n t i l ep l o t .
GPIHBP1 deletion mapping and pedigree analysis To
define the deletion breakpoints, oppositely oriented oligo-
nucleotides complementary to sequences flanking the
putative deletion were used to amplify the deletion junction.
The primers used to amplify the junction were as follows:
forward, 5′-GCATCAGGTATGAAGAGTTTGG-3′ and re-
verse, 5′-CAGGGTCTGTGTGGAAGAGG-3′.
Heparin infusion Fasting blood samples were collected
from each patient from a heparin lock. A total of 100 U/kg
heparin was infused intravenously (APP Pharmaceuticals,
Schaumburg, IL, USA). Venous blood samples were then
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J Inherit Metab Dis (2012) 35:531–540 533collected in citrate ethylenediaminetetraacetate (EDTA)
tubes 5, 10, 15, 30, 60, and 90 min after the heparin
infusion. Blood samples were maintained at 4°C, and
plasma was isolated by centrifugation within 30 min and
stored at −80°C. Triglyceride levels were measured using
the Vitros chemistry system (Ortho-Clinical Diagnostics,
Rochester, NY, USA) following the manufacturer’s protocol.
LPL and hepatic lipase (HL) mass were measured using a
direct sandwich enzyme-linked immunosorbent assay
(ELISA), as previously described (Bensadoun 1996; Peterson
et al. 1992).
Results
Infant presents with chylomicronemia
Proband 1 was a breast-fed male infant of Asian Indian
ancestry. The patient was the offspring of unrelated parents
with normal plasma triglyceride levels who both came from
a small town in Gujarat state in India. The patient presented
at 2 months of age with anemia, lethargy, and failure to
thrive. Sepsis was initially suspected and ruled out. His
plasma triglyceride level exceeded the limits of the assay
(>25,000 mg/dl), and his cholesterol level was 1,056 mg/dl.
Tests of liver and thyroid function were normal, as was the
urinalysis. Magnetic resonance imaging of his head
revealed an increase in lipid content in the central venous
sinus on T1-weighted images, as reported previously (Koral
et al. 2010).
The patient was placed on a low-fat diet and given fluids
intravenously. After 24 h, his plasma triglyceride level had
fallen to 19,960 mg/dl, with a plasma cholesterol level of
940 mg/dl. He was switched from Tolorex formula
(27 kcal/oz, 1.3% fat) to Portagen (Mead Johnson), a
milk-protein-based dietary formula that contains 40% fat
(with 87% from medium-chain triglycerides). He was
discharged after 12 days, with plasma triglyceride and
cholesterol levels of 1,615 mg/dl and 397 mg/dl, respectively.
At 16-months of age, the proband’s height was 73 cm
and he weighed 7.9 kg., which corresponds to the second
percentile for age and sex. He is on a fat-restricted diet
comprising Portagen, soy oil, and multivitamins. At 25-
months of age, his plasma triglyceride level was 905 mg/dl,
with total cholesterol of 146 mg/dl, HDL-cholesterol (C) of
16 mg/dl, and an low-density lipoprotein (LDL)-C level of
44 mg/dl.
No mutations identified in the coding regions of LPL,
APOA5, APOC2, or LMF1
The coding regions of LPL, APOA5, APOC2,a n dLMF1
were sequenced; no nonsynonymous mutations were identi-
fied that were not also present in dbSNP (Supplementary
Table 2).
Array-based copy-number detection reveals homozygosity
for GPIHBP1 deletion
The Illumina 1-M DNA BeadChip was used to screen for
copy number variations (CNV) across the genome. Probe
intensities were plotted as log ratios (logR) for each SNP
and mapped to the genome using the Illumina Genome
Viewer. A marked drop in the logR values was detected at
the distal end of the long arm of chromosome 8 (Fig. 1).
Probe intensity data was also analyzed using Partek
Genomic Suite software (v6.4). Genomic segmentation
algorithms were used to identify changes in DNA copy
number in the patient and compared with seven unrelated
individuals of European descent. A total of 12 probes at
8q24.3 had a mean copy number of 0.0062, suggesting with
a high degree of confidence (p=1.18e-6) that the patient
was homozygous for a deletion.
Two probes within the predicted deletion, rs35660224 and
rs11136270, had calculated logR values that were near the
normal range. Proband 1 had the lowest raw intensity (R
value) for these two probes (data not shown). Signal
intensities of these probes in proband 1 were 52.7% and
36.3% of the signal intensity measured in seven unrelated
individualsanalyzedsimultaneously.Thus,thesignaldetected
for these probes likely represents background noise.
Based on microarray data, the deletion was predicted to
be ∼18,400 bp in length and to contain the entire GPIHBP1
gene. The deletion breakpoints were sequenced and
mapped to the National Center for Biotechnical Information
(NCBI) reference genome (build 36.1). The deletion
spanned 17,499 bp and included GPIHBP1 (Fig. 2a). The
5′ breakpoint was located in a short interspersed nuclear
element (SINE) repeat. Although the 3′ breakpoint was not
in a repetitive sequence, both breakpoints occurred in an
identical 7-bp sequence (TGACCCT). The 7-bp motif was
1,124-bp upstream of exon 1 and 12,406-bp downstream of
exon 4. Only a single copy of the 7-bp motif was present at
the breakpoint of the deleted chromosome, making it
difficult to determine the exact position of the DNA
breakpoints (Fig. 2b).
We developed a PCR assay to screen for the deletion in
the family of proband 1 (Fig. 3a). When oligonucleotides
flanking the deletion were used to amplify the intervening
sequences, a PCR fragment of 481-bp was generated from
the deleted allele (Fig. 2c); the wild-type allele did not
generate a PCR fragment when the same oligonucleotides
were used, as they flanked a ∼18-kb interval. To detect the
wild-type allele, exon 1 of GPIHBP1 was amplified
(Fig. 2c). As expected, both of the proband’s parents were
heterozygous for the deletion, as were seven other family
534 J Inherit Metab Dis (2012) 35:531–540members (Fig. 3a). All family members heterozygous for
the deletion had normal plasma triglyceride levels. A 44-
year-old maternal aunt (III.9) was homozygous for the
deletion (Fig. 3a). She had a history of hypertriglyceridemia
and had pancreatitis at the age of 29 years. Her plasma
triglyceride level was 981 mg/dl when she was not taking
lipid-lowering medications.
This mutation was not found in the Database of
Genomic Variants. Two reports of copy-number gains of
GPIBHP1 but no reports of copy-number losses were
identified in the database (Kidd et al. 2008; Tuzun et al.
2005). The mutant GPIHBP1 alleles identified in proband 1
were presumably inherited from a common ancestor. To test
this hypothesis, we determined the extent of homozygosity
surrounding the deletion and distributions of the lengths of
regions of homozygosity (ROH) in proband 1 as well as in
six nonconsanguineous individuals of European descent
and one individual whose parents were second cousins
Fig. 2 Map of the deletion identified in patient 1. a Exons of
GPIHBP1 are shown as black boxes. Repetitive sequences were
identified and classified using RepeatMasker. Oligonucleotides flank-
ing the deletion were used to amplify the intervening sequences. The
5′ deletion junction was located in a mammalian interspersed repeat
(MIR) sequence, and the 3′ junction was in a noncoding sequence
located 12,406-bp downstream of GPIHBP1. b A 7-bp sequence,
TGACCCT, was present at each breakpoint of the normal allele and at
the junction in the deleted allele. c Polymerase chain reaction (PCR)
assays were performed to amplify the deletion and exon 1 of
GPIHBP1. The amplified fragments were size-fractionated on a 1%
agarose gel and the gel was stained with ethidium bromide. The
oligonucliotide primers flanking the junctions generate an amplicon of
481 bp only when the deletion is present; primers are too far apart to
amplify the ∼18-kb wild-type allele. Oligonucleotide primers flanking
exon 1 amplify a 381-bp fragment. A negative control reaction in
which no DNA was added to the reaction is shown
Fig. 1 Analysis of copy number
variation (CNV) in GPIHBP1
in patient 1. Log ratios [logR =
log2(sample intensity/expected
reference intensity)] were
calculated using the intensity
measures for each probe
(blue dot) within GenomeStudio
(Illumina). Calculated log ratios
were plotted genome wide and
annotated with known genes
using the Genome Browser
within GenomeStudio. A
smoothing line shown in red
was calculated using a 200-kb
sliding window. The region of
reduced logR values represents
the homozygous deletion, which
includes the GPIHBP1 gene
J Inherit Metab Dis (2012) 35:531–540 535(Supplementary Fig. 1). Regions of homozygosity were
identified from the Illumina genotypes using a Hidden
Markov Model implemented within Partek Genomics Suite
software. The homozygous deletion in proband 1 was
located within a ∼6.1-Mb ROH. This ROH was the largest
identified in the patient and nearly twice the length of the
largest region in controls. Furthermore, proband 1 had
nearly three times more large regions of homozygosity
(>2 Mb) than did any of the controls. Taken together, these
data indicate that the mutant GPIHBP1 alleles inherited by
proband 1 were derived from a common ancestor due to
recent inbreeding in the family.
Identification of a second patient with mutations
in GPIHBP1
DNA sequencing of patients from the Parkland Hospital
Outpatient Lipid Clinic who had type I hyperlipidemia
revealed GPIHBP1 mutations in a 36-year-old Hispanic
woman (proband 2), who was the sixth child of non-
consanguineous parents from two different towns in El
Salvador. The pedigree of her family is shown in Fig. 3b.
The proband (II.7) had a history of intermittent abdominal
pain from the age 11 years and was found to have
hypertriglyceridemia during her first pregnancy at age
24 years. She was hospitalized several times for pancreatitis
and placed on fish oil (2 g three times daily) and
gemfibrozil (600 mg twice daily). She was counseled to
follow a low-fat diet (∼12% fat) but continues to have
intermittent abdominal pain requiring analgesia. She had no
history of diabetes or eruptive xanthomas. An older brother
(II.5) also has a history of acute recurrent pancreatitis but
was not available for study (Fig. 3b).
At presentation, proband 2 weighed 63.5 kg and was
1.57 m tall [body mass index (BMI)=25.8 kg/m
2]. Physical
examination revealed lipemia retinalis and several eruptive
xanthomas on her elbows, but no hepatosplenomegaly. Her
plasma cholesterol was 544 mg/dl, with a triglyceride level
of 6,480 mg/dl. Liver function tests, fasting glucose,
hemoglobin A1c (5.8%), and urinalysis were within normal
limits. The coding regions of LPL, APOA5, APOC2, and
GPIHBP1 were sequenced (Supplementary Table 2). The
only nonsynonymous mutation identified was a homozy-
gous substitution in GPIHBP1 (c.203 G > A), which causes
cysteine at codon 68 to be replaced with tyrosine (C68Y).
This mutation was recently identified in a 30-year-old
Spanish woman with hypertriglyceridemia and pancreatitis
(Coca-Prieto et al. 2011).
Intravenously administered bolus of heparin did not increase
circulating levels of LPL in the two GPIHBP1-deficient
patients
To determine whether heparin would mobilize LPL from
peripheral tissues and attenuate the hypertriglyceridemia in
the two GPIHBP1-deficient patients, as had previously
Fig. 3 Pedigrees of patient 1
(A) and patient 2 (B). a Family
members of patient 1 were
assayed for the presence of the
deletion using the polymerase
chain reaction (PCR) assay de-
scribed in the legend of Fig. 2.
Family members heterozygous
and homozygous for the
deletion are designated with
half-filled and filled symbols,
respectively. b The brother of
patient 2 had a history of
pancreatitis. The only individual
available for analysis in this
family was the proband. Ages
and fasting plasma triglyceride
levels are provided. DM
diabetes mellitus, ND not
determined
536 J Inherit Metab Dis (2012) 35:531–540been observed in Gpihbp1
−/− mice (Weinstein et al. 2008),
we administered heparin as a bolus to both patients and
monitored the effect on blood levels of LPL and trigly-
cerides. A 44-year-old Caucasian man with a normal
plasma triglyceride level, and the 34-year-old father of
proband 1 (Fig. 3a, individual IV.4) were also studied as
controls. Heparin infusion caused a rapid increase in
immunodetectable LPL in both control individuals, but no
increase in LPL mass was apparent in the samples from the
GPIHBP1-deficient probands (Fig. 4a). The postheparin
plasma levels of HL increased 32-fold in the unrelated
control individuals and remained elevated during the 90-min
experiment. In both probands and in the proband’s father, HL
levelincreasedafterheparinadministrationthenfellslightlyto
lower levels (Fig. 4b). Postheparin plasma triglyceride levels
fell by ∼50% in both control individuals (Fig. 4c). The
maximum decreases in plasma triglyceride levels were 10%
in patient 1 and 20% in patient 2. (Fig. 4c). While this study
was being performed, two other groups reported that a bolus
of heparin failed to elicit appreciable increases of circulating
LPL in hypertriglyceridemic patients with mutations in
GPIHBP1 (Franssen et al. 2010;O l i v e c r o n ae ta l .2010).
Discussion
In this study, we identified and characterized the first
patient with complete deficiency of GPIHBP1 due to
homozygosity for a mutation that deletes the entire
GPIHBP1 gene. The patient presented at 2 months of age
with extremely severe hypertriglyceridemia (>25,000 mg/dl),
comparable with that found in the worst cases of LPL
deficiency. Thus, in contrast to mice, in which the hyper-
triglyceridemia associated with GPIHBP1 deficiency is
modest prior to weaning and becomes progressively more
severe with age (Beigneux et al. 2007), GPIHBP1 deficiency
is fully manifest in human infants. Prolonged infusion of
heparin has been shown to reduce plasma triglyceride levels
in GPIHBP1-deficient individuals (Franssen et al. 2010), but
infusion of a bolus of heparin into the two GPIHBP1-
deficient patients in our study confirmed that acute heparin
administration does not significantly lower plasma triglyceride
levels. Our results do not rule out the possibility that higher
dosesormoreprolongedadministrationofheparinmightcause
a reduction in plasma triglyceride level, as has been reported
previously (Franssen et al. 2010), although chronic high-dose
heparin treatment is accompanied by other significant risks.
Development has proceeded normally in patient 1 in our
study, and sequelae unrelated to hypertriglyceridemia have
not been noted in this patient or in other GPIHBP1-
deficient patients. Similarly, abnormalities reported to date
in mice lacking GPIHBP1 are all attributable to defects in
LPL function (Beigneux et al. 2007). Young and colleagues
Fig. 4 Plasma levels of lipoprotein lipase (LPL) (a), hepatic lipase
(HL) (b), and triglycerides (c) after an intravenous bolus injection of
heparin (100 U/kg). Blood was collected prior to (time 0) and at
multiple time points after, heparin injection. Plasma was separated by
centrifugation and used in each measurement. a LPL mass was
measured by sandwich enzyme-linked immunosorbent assay (ELISA)
(Peterson et al. 1992). b HL was measured using a sandwich ELISA
assay (Bensadoun 1996). c Plasma triglycerides were measured at
each time point and expressed as a proportion of the level at baseline
(time 0)
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mammalian species, including monotremes, but not in fish,
amphibians, or birds (Beigneux et al. 2009a). The recent
appearance of GPIHBP1 in vertebrate evolution is also
consistent with a highly specific function for the protein.
These findings, together with the observation that distribution
ofGPIHBP1expressionacrosstissues ingeneral parallels that
of LPL (Beigneux et al. 2009a) suggests that GPIHBP1 does
not have significant biological activity independent of its role
in LPL action.
Defining the extent of the physiological roles of
GPIHBP1 has important therapeutic implications. In
humans, the phenotype of GPIHBP1 deficiency appears
indistinguishable from that of LPL deficiency, whereas in
mice, the hypertriglyceridemia is milder at birth in the
Gpihbp
−/− mice than in the Lpl
−/− mice (Beigneux et al.
2007). If the protein functions solely to facilitate hydrolysis
of circulating triglycerides in humans, then GPIHBP1
deficiency should be fully treatable by lowering plasma
triglyceride levels.
The release of LPL into the circulation by heparin is
accompanied by a dramatic reduction in plasma triglyceride
levels (Korn 1955). The finding that heparin administration
also significantly reduces plasma triglyceride levels in
Gpihbp1-deficient mice raised the possibility that heparin
could be a potential therapy for GPIHBP1-deficient patients
(Weinstein et al. 2008). A recent study found that plasma
triglyceride levels could be markedly reduced by a 6-h
heparin infusion (from 1,780 to 534 mg/dl) but that little
reduction was seen at earlier time points (Franssen et al.
2010). When heparin was given to GPIHBP1-deficient
patients as a bolus, little LPL was released into the
circulation (Franssen et al. 2010; Olivecrona et al. 2010)
and data from our study confirm that a single bolus of
heparin does not significantly lower plasma triglyceride
levels in these patients.
The deletion in patient 1 involved two 7-bp sequences
that flank GPIHBP1 and are identical in sequence. The
upstream breakpoint is located in a mammalian interspersed
repeat (MIR), whereas the 3′ breakpoint is located 294 bp
downstream of another MIR repeat. MIR repeat elements
contain a tRNA-like domain and a “core” domain, followed
by a variable long interspersed element (LINE)-like region
(Gilbert and Labuda 1999). MIR repeats have been
documented to be directly involved in, or adjacent to,
breakpoints of deletions that cause a variety of other
diseases, including polycystic kidney disease (Bergmann
et al. 2005), phenylketonuria (Kozak et al. 2006), maturity-
onset diabetes of the young (MODY) (Ellard et al. 2007),
and congenital afibrinogenemia (Spena et al. 2004). It is
possible that the deletion observed in patient 1 occurred
as a result of MIR-mediated nonhomologous end joining
(Shaw and Lupski 2005; Toffolatti et al. 2002).
The parents of patient 1 were not known to be related but
were both from a small town within Gujarat state in
northwestern India. The high level of endogamy within
Indian subpopulations has resulted in distinct genetic
diversity between ethnicities (Indian Genome Variation
Consortium 2008) and a high prevalence of founder
mutations within particular communities (Colah et al.
2010; Zaidi et al. 2009). The region of homozygosity
surrounding the GPIHBP1 deletion in patient 1 extended
6.1 Mb, which is greater than expected when compared
with individuals of European ancestry. The presence of
longer-than-expected homozygous genomic segments in
patient 1 may reflect the local genetic substructure. The
multilineal inheritance of the deletion in this family is
consistent with this view. To more fully address this
question would require analysis and comparison of additional
individuals from this region of India.
We also identified an individual with chylomicronemia
who was homozygous for a C68Y mutation in GPIHBP1
that was previously identified in a Spanish woman with
chylomicronemia (Coca-Prieto et al. 2011). This mutation
is one of six in GPIHBP1 that have been identified in
patients with chylomicronemia (Table 1). A seventh
mutation, G56R, is likely not to be a causative mutation
for chylomicronemia, as reported (Gin et al. 2007; Wang
and Hegele 2007). All mutations, excluding the gene
deletion described in this study, are missense mutations
involving residues in the Ly6 domain of the protein. The
Ly6 domain contains ten highly conserved cysteine residues
that are predicted to form a three-fingered structure, based
on structural studies of other proteins with Ly6 domains
(Huang et al. 2007; Kjaergaard et al. 2008). Substitution of
alanine for any of these cysteines, including C68, does not
interfere with trafficking of GPIHBP1 in cultured cells but
abolishes LPL binding in a cell-free assay (Beigneux et al.
2009c). Olivicrona et al. (2010) identified three siblings
who were compound heterozygotes for mutations in two
different cysteine residues (C65S and C68G), and both of
these mutations were also associated with failure to bind
LPL.
The deletion of GPIHBP1 described in this study was
identified using microarray technology that provides effi-
cient high-resolution screening of copy number variation
across the entire human genome. Historically, copy number
variations have primarily been associated with sporadic
congenital syndromic disorders, but submicroscopic varia-
tions play an important role in several Mendelian disorders.
Some 5% of neurofibromatosis cases are caused by
deletions of the entire NF1 gene (Williams et al. 2009),
whereas ∼10–15% of familial hypercholesterolemia (Hobbs
et al. 1992) and 65% of Duchenne muscular dystrophy
(Prior and Bridgeman 2005) are due to gene deletions.
Analysis of several fully sequenced human genomes
538 J Inherit Metab Dis (2012) 35:531–540indicates that the number of submicroscopic deletions is far
greater than was previously recognized (Mills et al. 2011).
Thus, whereas the substantial majority of single gene
disorders are attributable to single nucleotide mutations,
the increasing resolution of copy number microarrays and
their widespread adoption for routine cytogenetic analysis
is likely to reveal a greater role for submicroscopic
deletions in Mendelian conditions as well as in sporadic
conditions and complex traits.
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